Allysta Pharmaceuticals

Leveraging Orphan Drug Status To Launch A Drug Pipeline

About this Event

Allysta Pharmaceuticals has developed a first-in-class therapeutic that has the potential to treat liver disease, lung fibrosis, and even heart disease. this drug has also achieved a rare disease designation for Duchenne Muscular Dystrophy allows for accelerated approvals and extended patent protections.

Preclinical tests have produced substantial data showing the treatment reduced muscle cell death, enhanced muscle regeneration, and reduced inflammation and fibrosis. They have observed improvement in muscle function, including strength and endurance. This suggests the ability of ALY688ER to alter the trajectory of the disease, potentially allowing boys to maintain muscle function and quality of life.

Join this Fireside Chat with:
  • Jason Dinges: Family Office VC, Morningside Technology Advisory
  • Dr. Henry Hsu: CEO, Allysta Pharmaceuticals

To hear how the company is leveraging Rare Disease Designation to help launch this pipeline as a product.

ALY688 has received Orphan Drug Designation for DMD from the FDA and is ready to begin Phase 1 clinical trials.

Register now to watch this webinar with Allysta Pharmaceutical CEO, Dr. Henry Hsu to learn how their first-in-class therapy improves in muscle function allowing boys to maintain muscle function and improve quality of life.

Hosted by Steven Saltzstein. CEO, Force Family Office

Video On Demand

– Recorded

June 19


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.